You are here: Industry Insights > Oxford Biomedica

News List

Gene genies: Oxford Biomedica and Homology Medicines create AAV business pharmatimes
January 28, 2022
Leading gene and cell therapy group, Oxford Biomedica, and Homology Medicines, have announced that the companies will establish...
Virica Biotech, Oxford Biomedica Enter R&D Partnership contractpharma
January 24, 2022
To improve the manufacturing of lentiviral vector gene therapies using viral sensitizers.
Oxford Biomedica and Novartis extend lentiviral vector manufacturing agreement CPhIonline
December 15, 2021
The new agreement extends to 2028 and allows Oxord Biomedica to work with other potential partners across all CAR-T targets
PhoreMost, Oxford Biomedica Announce Gene Therapy Discovery Collaboration americanpharmaceuticalreview
November 18, 2020
PhoreMost and Oxford Biomedica have entered into a discovery collaboration to develop next-generation CAR-T cell therapies. Financial details of the agreement are not disclosed.
PhoreMost, Oxford Biomedica Enter CAR-T Collaboration contractpharma
November 10, 2020
Aims to develop next-gen CAR-T cell therapies leveraging SITESEEKER and LentiVector platforms.
Oxford Biomedica enters Covid-19 vaccine manufacturing deal pharmaceutical-technology
September 02, 2020
Oxford Biomedica will reserve capacity for the vaccine candidate in up to three manufacturing suites at its Oxbox facility.
Oxford Biomedica and Beam Therapeutics sign CAR-T deal pharmatimes
August 04, 2020
UK-based Oxford Biomedica has signed a new development, manufacture and license agreement with Beam Therapeutics for next-generation CAR-T therapeutics.
Oxford Biomedica Signs Collaboration Agreement with VMIC contractpharma
June 15, 2020
Will work collaboratively to enable the manufacture of viral vector-based vaccines.
Oxford Biomedica partners VMIC for vaccine manufacturing pharmaceutical-technology
June 09, 2020
UK-based gene and cell therapy group Oxford Biomedica has partnered with non-profit Vaccines Manufacturing and Innovation Centre (VMIC) for the manufacturing of viral vector-based vaccines.
Oxford Biomedica joins consortium for coronavirus vaccine pharmaceutical-technology
April 09, 2020
UK-based gene and cell therapy group Oxford Biomedica has become part of a consortium focussed on the development, scale-up and production of a Covid-19 coronavirus vaccine candidate.

Previous page 1 2 Next page